FDA Grants Breakthrough Therapy and Fast Track Designations to Norroy Bioscience’s 68Ga-NYM096 for Clear Cell Renal Cell Carcinoma PET Imaging, First Chinese-Origin Radiopharmaceutical to Receive BTD

August 23, 2026

Targeted Oncology USA

Overview

The U.S. FDA has granted Breakthrough Therapy Designation (BTD) and Fast Track Designation (FTD) to Norroy Bioscience’s investigational PET imaging agent, 68Ga-NYM096, for detecting clear cell renal cell carcinoma (ccRCC). This designation is based on its potential to offer clinically significant advantages over existing diagnostic methods. Notably, this is the first FDA Breakthrough Therapy Designation for a radiopharmaceutical of Chinese origin. Preliminary clinical data presented at the 2026 AACR Annual Meeting demonstrated high sensitivity, specificity, and accuracy for 68Ga-NYM096.

In Depth

Key Findings

The U.S. Food and Drug Administration (FDA) has awarded both Breakthrough Therapy Designation (BTD) and Fast Track Designation (FTD) to 68Ga-NYM096, an investigational PET imaging agent developed by Norroy Bioscience for the detection of clear cell renal cell carcinoma (ccRCC). These designations are based on the promising potential of 68Ga-NYM096 to offer substantial clinical advantages over current diagnostic approaches for ccRCC.

Technical/Clinical Details

68Ga-NYM096 is a radiopharmaceutical imaging agent specifically designed to target Carbonic Anhydrase IX (CAIX), a protein highly expressed in ccRCC cells. By utilizing gallium-68 (68Ga) as a radioisotope, it enables high-resolution and quantitative imaging via PET scans. Preliminary clinical data, presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting, demonstrated that this agent exhibits superior sensitivity, specificity, and accuracy compared to conventional imaging modalities like CT and MRI in diagnosing and staging ccRCC. Its potential superiority is particularly noted in detecting micrometastases and assessing residual disease after treatment. The conferral of BTD and FTD signifies the FDA’s recognition of 68Ga-NYM096’s potential to address significant unmet medical needs in the diagnosis and management of ccRCC.

Background & Context

Clear cell renal cell carcinoma (ccRCC) is the most prevalent form of kidney cancer, where early detection and precise staging are crucial for guiding treatment strategies and predicting patient outcomes. However, current imaging techniques have limitations, and there is a pressing need for more sensitive and specific tools, especially for detecting small lesions and metastases. The BTD and FTD for 68Ga-NYM096 underscore the accelerating innovation in the radiopharmaceutical sector and contribute to the advancement of precision medicine. Furthermore, its distinction as the first FDA Breakthrough Therapy Designation for a radiopharmaceutical of Chinese origin highlights the growing international competitiveness and research prowess emanating from Asia in biopharmaceutical development.

Strategic Significance & Outlook

With both Breakthrough Therapy and Fast Track Designations, the FDA’s review process for 68Ga-NYM096 is expected to be significantly expedited, potentially allowing ccRCC patients earlier access to this innovative diagnostic tool. Norroy Bioscience will likely accelerate its clinical development program in close collaboration with regulatory authorities, aiming for eventual market approval. This technology is anticipated to become a vital instrument in standardizing ccRCC diagnostic protocols and supporting the selection of personalized treatment strategies, ultimately improving patient outcomes. Moreover, its potential application in other CAIX-positive tumors may also be explored, broadening its impact beyond ccRCC.

Source: https://www.targetedonc.com/view/fda-grants-breakthrough-therapy-fast-track-status-to-68ga-nym096-in-ccrcc

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.